Literature DB >> 12576927

Radiation enhancement by gemcitabine-mediated cell cycle modulations.

Stephan Mose1, Reiner Class, Hans-Walter Weber, Angelika Rahn, Luther W Brady, Heinz D Böttcher.   

Abstract

The purpose of this study was to investigate the exact dose dependency and time dependency of the radiation-enhancing effect of gemcitabine (2',2'difluoro desoxycytidine [dFdC]) in in vitro experiments (HeLa cells: cancer of the uterine cervix, #4197 cells: oropharyngeal squamous cell carcinoma), and to correlate this effect with the underlying changes in cell cycle distribution. Cell viability was determined fluorometrically after exposure to dFdC (0-20.0 micro mol/l), irradiation (0-37.5 Gy), and both modalities. Combining both therapies, cells were exposed to dFdC (0-10.0 micro mol/l) for 24 hours before further treatment and irradiated (0-30 Gy) immediately afterwards with or without removal of dFdC. For cell cycle analysis by flow cytometry, cells were irradiated (0-40 Gy) or treated with dFdC (0.012-1.0 micro mol/l, 24-48 hours). Additionally, cells were exposed to dFdC (2.0 micro mol/l, 0-4 hours). Cell cycle kinetics were evaluated using bromodeoxyuridine (BrdU) (10 micro mol/l) S-phase labeling, given either 30 minutes before or in the last hour of dFdC treatment (2.0 micro mol/l, 0-6 hours). The fluorometric assay revealed that dFdC enhances radiation-induced cytotoxicity at marginally toxic or nontoxic concentrations (<37 nmol/l). Radiation resulted in the anticipated G2/M arrest already at 2 Gy. DFdC induced concentration and exposure time-dependent cell cycle changes that were better resolved using BrdU, demonstrating a pronounced S-phase arrest already at 12 nmol/l. BrdU-pulse labeling revealed that the cell cycle block occurred at the G1/S boundary. Our data reconfirm the already known radiation enhancement, the S-phase specific activities of dFdC, and the relevance of the synchronized progression of cells through the S-phase with regard to the radiosensitizing properties of low-dose dFdC. However, we could demonstrate that before progressing in the S-phase, cells were blocked and partially synchronized at the more radiosensitive G1/S boundary. Furthermore, cells progressing past the block might accumulate proapoptotic signals caused by both radiation and dFdC, which will also results in cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576927     DOI: 10.1097/00000421-200302000-00013

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation.

Authors:  Neil A Demarse; Suriyan Ponnusamy; Eleanor K Spicer; Elif Apohan; John E Baatz; Besim Ogretmen; Christopher Davies
Journal:  J Mol Biol       Date:  2009-10-02       Impact factor: 5.469

2.  The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.

Authors:  Bea Pauwels; Annelies E C Korst; Greet G O Pattyn; Hilde A J Lambrechts; Juliette A E Kamphuis; Christel M J De Pooter; Godefridus J Peters; Filip Lardon; Jan B Vermorken
Journal:  BMC Cancer       Date:  2006-05-30       Impact factor: 4.430

3.  Antiproliferative Activity of the Chinese Medicinal Compound, Delisheng, Compared With Rg3 and Gemcitabine in HepG2 Cells.

Authors:  S H Wang; Y C Wang; Y L Nie; Y N Hai; H F Sun; Z L Yuan; K J Nan
Journal:  Indian J Pharm Sci       Date:  2013-09       Impact factor: 0.975

4.  The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas.

Authors:  S J Rogers; N R Datta; E Puric; O Timm; D Marder; S Khan; C Mamot; J Knuchel; A Siebenhüner; B Pestalozzi; M Guckenberger; S Bodis; O Riesterer
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-25

5.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

6.  Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway.

Authors:  Quqing Song; Sheng Jiang; Xinxin Zhang; Chunxia Pan; Chunhua Lu; Jingwei Peng; Qingshui Li
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

7.  "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.

Authors:  Niloy Ranjan Datta; Bernhard Pestalozzi; Pierre-Alain Clavien; Alexander Siebenhüner; Emsad Puric; Shaka Khan; Christoph Mamot; Oliver Riesterer; Jürg Knuchel; Cäcilia Sophie Reiner; Stephan Bodis
Journal:  Radiat Oncol       Date:  2017-11-21       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.